Obermatt
See Similar Stocks →

Flags

Financial distress

MDxHealth

NAQ:MDXH · BE0974461940
BiotechnologySmall

360

43
Profit price38
Owner Earnings Yield1
Dividend Yield1
Price/Sales100
EV / Gross Profit83
Price/Book74
Return on Capital78
Cash Return on Capital51
Profit margins86
Accruals39
Owner Earnings Margin80
Sales growth50
Profit growth62
Reinvestment75
Price momentum5
Debt load10
Refinancing1
Debt Payback1
Liquidity58
Analyst ratings68
Expectations trend20
Market mood85
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

MDxHealth doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryBelgium
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded2003
Employees246
Websitemdxhealth.com
ISINBE0974461940
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Health DiagnosticsUrologyGeneticsOncologyMedical

Description

MDxHealth SA is a commercial-stage precision diagnostics company providing non-invasive, clinically actionable, and cost-effective urologic solutions to improve patient care. The company’s core menu of testing solutions, Confirm mdx for Prostate Can…

Analysis

Middle-of-the-road

MDxHealth SA sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 4/20 on our value-creation score: not creating value.

Flags to be aware of: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
57
2026

All-time high

73

Mar 2026

All-time low

57

Jun 2026

Average rank

65

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
100
—
—
—
Price/Earnings
49
—
—
—
Price/Book
74
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
87
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare MDxHealth with its peers
Qiagen
GER:QIA
81
CountryNetherlands
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
AC Immune
NMQ:ACIU
68
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Heidelberg Pharma
GER:HPHA
32
CountryGermany
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Uniqure
NSQ:QURE
20
CountryNetherlands
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Genfit
PAR:GNFT
32
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
ProQR Therapeutics
NAQ:PRQR
19
CountryNetherlands
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →